Recurrent differentiated thyroid cancer: towards personalized treatment based on evaluation of tumor characteristics with PET

Recurrent differentiated thyroid cancer: towards personalized treatment based on evaluation of tumor characteristics with PET - THYROPET

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON38034

Enrollment

100

Registered

2012-06-26

Start date

2012-12-06

Completion date

Unknown

Last updated

2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Differentiated tyroid carcinoma thyroid cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Patients with a history of differentiated thyroid cancer 2. After complete thyroidectomy and ablation of functional remnants with 131I. 3. Planned for blind high dose 131I treatment based on biochemically suspected recurrence, defined as a Tg-level above 2.0 ng/ml. 4. Ultrasonography of the neck performed

Exclusion criteria

Exclusion criteria: 1. Age

Design outcomes

Primary

Measure	Time frame
- The number of futile 131I treatments that can be avoided using this imaging strategy.	—

Secondary

Measure	Time frame
- Synchronised introduction and QA/QC of 124I-PET in the Netherlands - Translational correlation of 124I-PET and FDG-PET with histopathology (where available) and treatment outcome, in an explorative setting. - To investigate whether 124I-PET has the same diagnostic, dosimetric and prognostic yield during stimulation with rhTSH and hormone withdrawal combined with low-idodine diet.	—

Countries

Netherlands

Outcome results